Format

Send to

Choose Destination
Ann Intern Med. 2000 Apr 18;132(8):661-8.

The Lyme disease vaccine: conception, development, and implementation.

Author information

1
Section of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut 06519, USA.

Abstract

In the past 20 years, remarkable strides have been made toward understanding and preventing Lyme disease in humans. In December 1998, the U.S. Food and Drug Administration approved a recombinant outer surface protein A vaccine against Lyme disease (LYMErix, SmithKline Beecham, Philadelphia, Pennsylvania). The vaccine, which is derived from a lipidated outer surface protein of the causative spirochete Borrelia burgdorferi, is important because it may decrease the morbidity and financial costs associated with Lyme disease. Its mechanism is unique because it works inside the tick vector itself, preventing the human from becoming infected.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center